Supriya Lifescience Ltd

- The company plans capex of around INR100-120 crores for Module E at the Parshuram plant, mostly funded from IPO proceeds, indicating no immediate equity raise for this. - Additional capex of about INR60 crores is planned for Ambernath site expansion with environment clearance. - For the current fiscal year (FY24), capex is expected at around INR105-110 crores, and a similar amount is planned for FY25. - There is no explicit mention of any new fundraising through debt or equity in the near term. - The company appears to be funding expansions primarily through internal accruals and existing IPO proceeds. Summary: No new debt or equity fundraising is indicated currently; expansions are being funded largely through IPO proceeds and internal funds.

- Planned capex of around INR 105-120 crores in Q1 FY'25, mainly for Module E at the Lote Parshuram site. - Majority of this capex funded from IPO proceeds. - Module E is a new dedicated production block with ~350 KL capacity, expected operational by Q1 FY'25. - Ambernath greenfield site refurbished for bottling activities and API R&D; operational also by Q1 FY'25. - Additional INR 60 crores capex over the next two years planned for Ambernath site to support CDMO/CMO activities, especially anaesthetic product bottling. - Refurbishment planned for older modules (ABC) in the next fiscal. - Capex expansion is modular and phased, aligned with utilization and orders. - Asset turns target of 2.5x and above from this capex. - Expansion aims to support revenue growth to INR 1,000 crores by FY'27 and strengthen backward integration and new product launches.

- Supriya Lifescience aims to achieve INR 1,000 crores+ revenue by FY'27, driven by existing products, new product launches, and CDMO/CMO business. - Sustained year-on-year revenue growth of 20%-23% is targeted over the next three years. - Contribution from CMO/CDMO, especially the anaesthetic product (a $300 million global market), is expected to be significant and could exceed conservative projections. - Existing top products are growing at 5%-10%, with some products growing at around 8%-10%. - Addition of 4-5 new products annually via enhanced R&D. - Europe sales have increased substantially, indicating improved traction in regulated markets like Europe and North America. - Capacity expansion (including new module E with 350 KL added capacity) will double overall capacity, supporting volume growth. - New product categories include anaesthetics, anti-diabetic, and anti-anxiety therapies.

- Supriya Lifescience expects revenue growth of around 20% annually over the next three years. - The company aims to achieve INR 1,000 crores revenue by FY'27, driven by existing products and new launches. - Sustainable EBITDA margins are guided between 28%-30%, expected to be stable across quarters. - Some individual projects, especially in CDMO/CMO, may have higher margins but blended portfolio margin guidance remains conservative. - Profit before tax grew around 217% in Q3 FY24 compared to Q3 FY23; PAT margin improved to 21.6%. - Continued product launches and expansion, including module E and Ambernath facility, will support growth. - CDMO business launch expected to enhance revenues, though initial utilization may ramp up over 2-3 years. - Management maintains a cautious but optimistic approach, focusing on diversified markets and sustainable margin profile.

- Supriya Lifescience has received the first commercial order from DSM Firmenich and has a good forecast for the next financial year. - The DSM Firmenich contract at full capacity has an estimated potential of INR 60-70 crores. - Advanced-level discussions are ongoing for bottling anesthetic products at the new Ambernath facility. - No concrete CDMO/CMO orders are currently finalized for Ambernath; utilization ramp-up expected over 2-3 years due to regulatory inspections. - Whey protein project recently completed equipment installation; trial batches supplied to distributors with plans to commercialize by Q2 FY'25. - New product registrations and filings are progressing, boosting future order prospects. - Overall, order visibility is strengthening with expanding contracts and promising pipeline in both API and CDMO segments.